See more : Smart Decision, Inc. (SDEC) Income Statement Analysis – Financial Results
Complete financial analysis of Pacira BioSciences, Inc. (PCRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacira BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Dave Inc. (DAVEW) Income Statement Analysis – Financial Results
- Sirius Real Estate Limited (SRE.L) Income Statement Analysis – Financial Results
- HORNBACH Holding AG & Co. KGaA (HBH.DE) Income Statement Analysis – Financial Results
- Isodiol International Inc. (ISOLF) Income Statement Analysis – Financial Results
- Arista Power, Inc. (ASPW) Income Statement Analysis – Financial Results
Pacira BioSciences, Inc. (PCRX)
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.98M | 666.82M | 541.53M | 420.83M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M | 39.08M | 15.69M | 14.56M | 15.01M | 13.93M |
| Cost of Revenue | 184.67M | 199.30M | 140.26M | 117.33M | 106.71M | 86.85M | 87.92M | 110.10M | 71.84M | 77.44M | 54.77M | 32.14M | 16.74M | 12.28M | 12.30M | 17.46M |
| Gross Profit | 490.31M | 467.53M | 401.28M | 303.50M | 314.31M | 250.43M | 198.72M | 166.27M | 177.16M | 120.23M | 30.78M | 6.95M | -1.05M | 2.29M | 2.71M | -3.54M |
| Gross Profit Ratio | 72.64% | 70.11% | 74.10% | 72.12% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.70% | 18.03% | -25.41% |
| Research & Development | 76.26M | 84.80M | 55.55M | 59.42M | 72.12M | 55.69M | 57.29M | 45.68M | 28.66M | 18.73M | 21.56M | 9.94M | 14.87M | 18.63M | 26.23M | 33.21M |
| General & Administrative | 116.40M | 109.52M | 88.32M | 74.83M | 71.12M | 70.16M | 66.69M | 63.40M | 61.31M | 41.65M | 20.96M | 15.97M | 20.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 153.04M | 145.00M | 111.02M | 118.68M | 129.66M | 107.11M | 94.80M | 89.22M | 77.73M | 65.01M | 41.55M | 30.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 269.44M | 254.52M | 199.35M | 193.52M | 200.78M | 177.27M | 161.49M | 152.61M | 139.04M | 106.66M | 62.51M | 46.31M | 20.16M | 6.03M | 5.02M | 8.61M |
| Other Expenses | 56.94M | 57.29M | 13.55M | 7.87M | 5.70M | -888.00K | 167.00K | -82.00K | -165.00K | -159.00K | -47.00K | -111.00K | 3.02M | 6.03M | 5.02M | 8.61M |
| Operating Expenses | 402.63M | 396.60M | 268.44M | 260.80M | 278.60M | 232.95M | 218.78M | 198.29M | 167.71M | 125.39M | 84.07M | 56.24M | 35.03M | 24.66M | 31.25M | 41.83M |
| Cost & Expenses | 587.30M | 595.90M | 408.70M | 378.13M | 385.32M | 319.80M | 306.70M | 308.40M | 239.54M | 202.83M | 138.84M | 88.38M | 51.77M | 36.93M | 43.55M | 59.29M |
| Interest Income | 11.44M | 4.54M | 896.00K | 4.63M | 7.38M | 6.50M | 4.08M | 1.32M | 678.00K | 382.00K | 259.00K | 275.00K | 255.00K | 146.00K | 77.00K | 235.00K |
| Interest Expense | 20.31M | 39.98M | 31.75M | 25.67M | 23.63M | 21.95M | 18.05M | 7.06M | 7.73M | 8.28M | 7.25M | 1.81M | 4.78M | 4.89M | 3.60M | 3.49M |
| Depreciation & Amortization | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.17M | 13.83M | 12.92M | 11.48M | 10.04M | 5.75M | 5.65M | 4.31M | 4.25M | 4.43M | 3.83M |
| EBITDA | 157.58M | 144.78M | 118.47M | 71.42M | 55.29M | 33.06M | -10.59M | -17.86M | 21.39M | 5.09M | -50.73M | -44.55M | -34.23M | -19.12M | -24.12M | -41.53M |
| EBITDA Ratio | 23.35% | 18.22% | 26.71% | 15.89% | 10.41% | 6.85% | -5.52% | -11.14% | 4.00% | -2.50% | -55.32% | -125.71% | -185.14% | -124.20% | -163.15% | -296.65% |
| Operating Income | 87.68M | 60.02M | 131.07M | 46.35M | 38.11M | 15.92M | -24.94M | -32.02M | 9.46M | -5.17M | -53.29M | -49.30M | -39.10M | -22.37M | -28.55M | -45.36M |
| Operating Income Ratio | 12.99% | 9.00% | 24.20% | 11.01% | 9.05% | 4.72% | -8.70% | -11.59% | 3.80% | -2.61% | -62.29% | -126.13% | -249.23% | -153.63% | -190.24% | -325.77% |
| Total Other Income/Expenses | -25.97M | -46.72M | -33.52M | -26.26M | -26.66M | -16.34M | -17.53M | -5.82M | -7.34M | -8.38M | -11.06M | -2.98M | -4.23M | -4.78M | -3.16M | 3.50M |
| Income Before Tax | 61.70M | 13.30M | 56.40M | 20.09M | -10.75M | -425.00K | -42.47M | -37.84M | 2.12M | -13.54M | -64.35M | -52.28M | -43.33M | -27.15M | -28.18M | -45.59M |
| Income Before Tax Ratio | 9.14% | 1.99% | 10.42% | 4.77% | -2.55% | -0.13% | -14.82% | -13.69% | 0.85% | -6.85% | -75.22% | -133.77% | -276.17% | -186.44% | -187.80% | -327.38% |
| Income Tax Expense | 19.75M | -2.61M | 14.42M | -125.43M | 268.00K | 46.00K | 140.00K | 105.00K | 264.00K | 173.00K | -442.00K | -3.95M | 7.25M | 4.78M | 3.16M | -3.50M |
| Net Income | 41.96M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M | 1.86M | -13.72M | -63.91M | -52.28M | -43.33M | -27.15M | -31.71M | -41.86M |
| Net Income Ratio | 6.22% | 2.39% | 7.75% | 34.58% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% | -186.44% | -211.30% | -300.62% |
| EPS | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| Weighted Avg Shares Out | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.20M | 36.54M | 35.17M | 33.11M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
| Weighted Avg Shares Out (Dil) | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.30M | 35.30M | 33.18M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13,...
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacira (PCRX) Matches Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m....
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29,...
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier,...
Source: https://incomestatements.info
Category: Stock Reports